Cargando…
Modeling and antitumor studies of a modified L–penetratin peptide targeting E2F in lung cancer and prostate cancer
E2F1-3a overexpression due to amplification or to mutation or loss of the retinoblastoma gene, induces genes involved in DNA synthesis and leads to abnormal cellular proliferation, tumor growth, and invasion. Therefore, inhibiting the overexpression of one or more of these activating E2Fs is a recog...
Autores principales: | Shaik, Tazeem, Rather, Gulam M., Bansal, Nitu, Minko, Tamara, Garbuzenko, Olga, Szekely, Zoltan, Abali, Emine E., Banerjee, Debabrata, Kerrigan, John E., Scotto, Kathleen W., Bertino, Joseph R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161789/ https://www.ncbi.nlm.nih.gov/pubmed/30279956 http://dx.doi.org/10.18632/oncotarget.26064 |
Ejemplares similares
-
A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts
por: Xie, Xiaoqi, et al.
Publicado: (2014) -
Anti-Tumor Effects of a Penetratin Peptide Targeting Transcription of E2F-1, 2 and 3a Is Enhanced When Used in Combination with Pemetrexed or Cisplatin
por: Rather, Gulam Mohmad, et al.
Publicado: (2021) -
A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma
por: Rather, Gulam M., et al.
Publicado: (2019) -
Activated matriptase as a target to treat breast cancer with a drug conjugate
por: Rather, Gulam M., et al.
Publicado: (2018) -
Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)